Pasithea Therapeutics Warrants
KTTAW
5 hedge funds and large institutions have $240K invested in Pasithea Therapeutics Warrants in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.
457% more capital invested
Capital invested by funds: $43.1K → $240K (+$197K)
6.21% more ownership
Funds ownership: 0% → 6.21% (+6.2%)
0% more funds holding
Funds holding: 5 → 5 (0)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$25 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$311 |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$30 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $148K | – | – | – |
|
|
KC
2
Kepos Capital
New York
| $50K | – | – | – |
|
|
WAM
3
Warberg Asset Management
Winnetka,
Illinois
| $40K | -$30 | -300 | -0.1% |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $2K | -$311 | -3,150 | -23% |
|
|
5
UBS Group
Zurich,
Switzerland
| – | +$25 | +250 | +16% |
|
KTTAW Hedge Fund Activity: Q3 2022 in Review
5 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q3 2022, worth a combined $240K — up 457% from $43.1K a quarter earlier.
Fund positioning in KTTAW was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, adding an estimated $25. The largest seller was Susquehanna International Group, cutting an estimated $311.
- 5 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $240K of Pasithea Therapeutics Warrants stock for Q3 2022, up 457% quarter-over-quarter.
- 0 funds opened new Pasithea Therapeutics Warrants positions in Q3 2022 and 0 closed out.
- The largest Pasithea Therapeutics Warrants buyer in Q3 2022 was UBS Group, an estimated $25 added.
- The largest Pasithea Therapeutics Warrants seller in Q3 2022 was Susquehanna International Group, an estimated $311 sold.
Based on aggregated 13F filings for Q3 2022.